肝细胞癌的 TCR 细胞免疫治疗：进展、挑战与前景

← 返回前沿论文

肝细胞癌的 TCR 细胞免疫治疗：进展、挑战与前景

英文原题：TCR-based cellular immunotherapy for hepatocellular carcinoma: advances, challenges, and prospects.

PubMed 2025/07/01（内容时间） Cancer Immunol Immunother Q1 · IF 5.8（JCR 2025）

技术：TCR-T 肝细胞癌地区：中国

登录后收藏与关注全文解读加入对比

研究概要

本综述从抗原靶向的角度全面审视了TCR-T疗法治疗HCC的研究进展。

中文摘要

肝细胞癌（HCC）是全球最常见的恶性肿瘤之一。然而，当前的一线治疗模式未能取得令人满意的疗效。近年来，T细胞受体（TCR）-T疗法作为一种有前景的治疗方法日益受到关注。本综述概述了HCC的流行病学，评估了当前一线治疗方案的疗效，并介绍了过继性细胞疗法（ACTs），特别聚焦于TCR-T疗法。值得注意的是，我们按靶向不同抗原对现有用于治疗HCC的TCR-T研究进行了分类，涵盖已发表的文献和已注册的临床试验。此外，我们讨论了当前TCR-T研究和应用的局限性，同时对未来的研究方向和发展前景提出了见解。总之，本综述从抗原靶向的角度全面审视了TCR-T疗法治疗HCC的研究进展。尽管仍有若干挑战有待解决，但我们相信TCR-T疗法是治疗HCC的一种有前景的方法。

展开英文摘要原文

Hepatocellular carcinoma (HCC) ranks among the most prevalent malignant tumors globally. However, current frontline treatment modalities fail to achieve satisfactory therapeutic outcomes. In recent years, T-cell receptor (TCR)-T therapy has garnered increasing attention as a promising therapeutic approach. This review provides an overview of the epidemiology of HCC, evaluates the efficacy of current first-line treatment options, and introduces adoptive cellular therapies (ACTs), with a specific focus on TCR-T therapy. Notably, we categorize existing TCR-T research targeting different antigens for the treatment of HCC, covering both published literature and registered clinical trials. Furthermore, we discuss the limitations of current TCR-T research and applications, while offering insights into future research directions and development prospects. In summary, this review comprehensively examines the research progress on TCR-T therapy for HCC from the perspective of antigen targeting. Although several challenges remain to be addressed, we believe that TCR-T therapy represents a promising approach for the treatment of HCC.

论文信息

作者: Zeng W、Zhu W、Yuan G、Chen J、Wang Z、Hou J、Jiang DK
第一作者单位: State Key Laboratory of Organ Failure Research, Key Laboratory of Infectious Diseases Research in South China, Ministry of Education; Guangdong Provincial Key Laboratory for Prevention and Control of Major Liver Diseases, Guangdong Provincial Clinical Research Center for Viral Hepatitis, Guangdong Institute of Hepatology, Guangdong Provincial Research Center for Liver Fibrosis Engineering and Technology, Department of Infectious Diseases and Hepatology Unit, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.China
通讯作者单位: State Key Laboratory of Organ Failure Research, Key Laboratory of Infectious Diseases Research in South China, Ministry of Education; Guangdong Provincial Key Laboratory for Prevention and Control of Major Liver Diseases, Guangdong Provincial Clinical Research Center for Viral Hepatitis, Guangdong Institute of Hepatology, Guangdong Provincial Research Center for Liver Fibrosis Engineering and Technology, Department of Infectious Diseases and Hepatology Unit, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China. dekejiang17@smu.edu.cn.China
文献类型: 综述
期刊: Cancer immunology, immunotherapy : CII2025 Jul 1

原文标识: PubMed 40590989　·　DOI 10.1007/s00262-025-04122-z

在 PubMed 查看 → 出版商原文（DOI）报告译文或资料问题 →